LTFS
PCRX icon

Ladenburg Thalmann Financial Services’s Pacira BioSciences PCRX Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$89K Buy
1,968
+233
+13% +$9.9K ﹤0.01% 3115
2019
Q3 		$66K Sell
1,735
-1
-0.1% -$40 ﹤0.01% 3236
2019
Q2 		$76K Sell
1,736
-221
-11% -$9.38K ﹤0.01% 3171
2019
Q1 		$74K Sell
1,957
-17
-0.9% -$664 ﹤0.01% 3113
2018
Q4 		$85K Sell
1,974
-81
-4% -$3.78K ﹤0.01% 2863
2018
Q3 		$101K Buy
2,055
+336
+20% +$14.5K ﹤0.01% 2808
2018
Q2 		$54K Hold
1,719
– – ﹤0.01% 3203
2018
Q1 		$54K Hold
1,719
– – ﹤0.01% 3203
2017
Q4 		$78K Sell
1,719
-893
-34% -$35.4K ﹤0.01% 2899
2017
Q3 		$98K Sell
2,612
-1,491
-36% -$60K ﹤0.01% 2617
2017
Q2 		$196K Sell
4,103
-86
-2% -$3.99K ﹤0.01% 2037
2017
Q1 		$190K Buy
4,189
+2,212
+112% +$95.6K ﹤0.01% 1952
2016
Q4 		$66K Buy
1,977
+45
+2% +$1.5K ﹤0.01% 2643
2016
Q3 		$67K Buy
1,932
+374
+24% +$14.7K ﹤0.01% 2556
2016
Q2 		$52K Sell
1,558
-1,335
-46% -$65.6K ﹤0.01% 2644
2016
Q1 		$153K Sell
2,893
-535
-16% -$31.3K ﹤0.01% 1788
2015
Q4 		$264K Buy
3,428
+763
+29% +$43.2K ﹤0.01% 1397
2015
Q3 		$109K Buy
2,665
+118
+5% +$7.23K ﹤0.01% 1917
2015
Q2 		$180K Buy
2,547
+23
+0.9% +$1.81K ﹤0.01% 1681
2015
Q1 		$224K Buy
2,524
+804
+47% +$81.6K ﹤0.01% 1502
2014
Q4 		$152K Buy
1,720
+170
+11% +$16.1K ﹤0.01% 1620
2014
Q3 		$150K Buy
1,550
+100
+7% +$9.73K ﹤0.01% 1366
2014
Q2 		$133K Hold
1,450
– – ﹤0.01% 1424
2014
Q1 		$101K Buy
1,450
+1,400
+2,800% +$95.2K ﹤0.01% 1499
2013
Q4 		$3K Hold
50
– – ﹤0.01% 3422
2013
Q3 		$2K Buy
+50
New +$1.82K ﹤0.01% 3465

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Ladenburg Thalmann Financial Services's PCRX Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services increased its Pacira BioSciences (PCRX) stake by 13% in Q4 2019, buying an estimated $9.9K and bringing the position to 1,968 shares worth $89K. The position accounts for ﹤0.01% of the portfolio, ranked #3115.

Ladenburg Thalmann Financial Services first reported a position in PCRX in Q3 2013 and has held it in 26 quarters since. The position peaked at $264K in Q4 2015. 231 funds tracked by Wall St. Rank hold PCRX as of Q4 2019.

  • Ladenburg Thalmann Financial Services held 1,968 shares of Pacira BioSciences worth $89K as of Q4 2019.
  • Ladenburg Thalmann Financial Services bought 233 Pacira BioSciences shares in Q4 2019, an estimated $9.9K.
  • Pacira BioSciences made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #3115 holding.
  • Ladenburg Thalmann Financial Services first reported a position in Pacira BioSciences in Q3 2013 and has held it in 26 quarters since.
  • Ladenburg Thalmann Financial Services's Pacira BioSciences position peaked at $264K in Q4 2015.
  • 231 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.